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ABSTRACT 
Regulating Distinct Cell Lineages in the Pancreatic Islet 
Joshua A Levine 
 
Type I and type II diabetes mellitus are associated with a loss of functioning insulin-
producing β cells in the pancreas. Understanding the mechanism of normal islet and β 
cell development will be an important step in developing possible treatments for the 
disease.  Nkx2.2 is essential for proper β cell differentiation.  Nkx2.2-/- mice show a 
complete absence of insulin-producing β cells, a 90% reduction of glucagon-producing α 
cells, and an increase in ghrelin-producing cells.  Nkx2.2 contains three conserved 
domains: the tinman domain (TN), homeodomain (HD), and NK2-specific domain (SD).  
The SD domain is highly conserved among Nk2 family members and across species. 
However, its function remains largely unknown.  In order to further understand the 
molecular interactions involving Nkx2.2 in the developing mouse pancreas, we have 
generated a mouse line containing mutations in the NK2-SD domain. We show that SD 
mutant mice have a decrease in β cell numbers as well as a decrease in the β cell markers, 
NeuroD, Nkx6.1, Ins1 and Ins2.  However, there is no change in α cell numbers or the α 
cell markers, Glucagon and Irx2.  Unlike the persistent upregulation of ghrelin in the 
Nkx2.2-/- mice, Nkx2.2SD/SD mice display a transient increase in ghrelin expression, which 
normalizes by birth.  Additionally, polyhormonal cells are seen as early as e12.5 and 
persist postnatally.  Postnatally, the mice show morphological changes in islet size and 
the proximity of their islets to the ducts.  Moreover, they show a continuing loss of β cells 
and the persistence of polyhormonal cells resulting in severe hyperglycemia.  
Mechanistically, Nkx2.2 has been shown to interact in a protein complex involving 
several methylation factors.  We show that the SD domain is necessary for the interaction 
of Nkx2.2 and Dnmt1, the maintenance methyltransferase.  We further show that there is 
a loss of methylation in the a cell gene Arx in sorted β cells of the Nkx2.2SD/SD mice as 
well as global hypomethylation in the Nkx2.2SD/SD mice.  These data suggest that Nkx2.2 
is responsible for proper methylation patters of islet specific genes in the developing 
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 The mouse pancreas is a dual organ that lies between the stomach, spleen, and small 
intestine.  95% of the pancreas consists of exocrine tissue, which is responsible for the secretion 
of enzymes that are necessary for digestion.  The other 5% of the pancreas consists of the 
endocrine compartment, which is responsible for glucose homeostasis and consists of clusters of 
cells called the Islets of Langerhans.  The adult islet is composed of 4 cell types.  80% of the islet 
consists of a core of insulin-producing β cells.  The remainder of the islet cells surround this core 
and consist of the glucagon-producing α cell, the somatostatin-producing δ cell, and the 
pancreatic polypeptide-producing PP cell.  A fifth cell type, the ghrelin-producing ε cell, is found 
only in the embryonic pancreas.  A portion of these ghrelin expressing cells co-express glucagon 
during development, but after birth ghrelin is turned off while glucagon expression remains.  The 
remaining ghrelin-expressing cells differentiate into PP cells (Arnes et al., 2012, in press).   
 
Diabetes Mellitus 
 25 million people in the United States are currently afflicted with Diabetes mellitus.  
Moreover, 79 million others are considered to be prediabetic with a high likelihood of 
progressing to a full-fledged diabetic state.  Diabetes is the seventh leading cause of death in the 
United States and is the leading cause of kidney failure, nontraumatic lower limb amputation, 
and blindness.  Diabetes is also a major cause of heart disease and stroke (CDC 2011).  It is of 
great interest to understand the disease and the possible modes of treatment.   
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 Diabetes mellitus consists of two main subgroups, Type 1 and Type II diabetes.  Type I 
diabetes (T1DM) is caused by the autoimmune destruction of the insulin producing β cells in the 
pancreatic islet (Bottazzo et al., 1974; MacCuish et al., 1974).  Type II diabetes (T2DM) is a 
multifactorial disease associated with insulin resistance in the periphery, predominantly in the 
liver, muscle, and adipose tissue.  Prolonged insulin resistance can result in increasing 
hyperglycemia and eventually induce β cells to proliferate and/or produce increasing amounts of 
insulin.  Over time, the β cells cannot support the increased insulin demand and begin to die or 
dedifferentiate, resulting in a lack of endogenous insulin and necessitating exogenous sources of 
insulin (Butler et al., 2003a; Butler et al., 2003b; Ritzel and Butler, 2003; Talchai et al., 2012; 
Vaxillaire et al., 2009; Yoon et al., 2003).  Although T1DM and T2DM have differing etiologies, 
both eventually result in the loss of healthy β cells causing hyperglycemia which, when left 
untreated, results in vascular complications and eventually leads to death.  A third type of 
diabetes, mature onset diabetes of the young (MODY), which affects a relatively small 
percentage of overall diabetic cases, is a result of monogenic mutations.  These mutations lead to 
a vastly different course of hyperglycemia and have allowed many interesting insights into the 
genes that are affected [reviewed in (Vaxillaire et al., 2009)].  For example, MODY 2 is caused 
by mutations in the GCK gene, a protein needed for proper β cell function.  Because it is not 
needed for differentiation of the β cell, patients experience mild fasting hyperglycemia 
throughout life.  MODY 4, on the other hand, is caused by mutations in PDX1, a transcription 
factor that is indispensible for pancreatic formation.  Patients experience more severe 
hyperglycemic events and when mutations are homozygous, pancreatic agenesis occurs.  By 
understanding the phenotypes associated with each case of MODY, one can begin to understand 
how the affected gene functions in β cell development and function. 





T1DM occurs when autoimmune destruction of the insulin producing β cells leads to a 
lack of endogenous insulin and consequent hyperglycemia.  Therefore, the main method of 
glucose management is administration of exogenous insulin to maintain euglycemia.  Although 
strict control is theoretically ideal, hypoglycemia is a warranted risk as administering too much 
insulin is possible.  Therefore, a combination of medium length acting insulin to replace basal 
insulin levels and short-acting insulin to compensate for mealtime insulin has been in practice for 
many years (Murphy et al., 2003).  More recently, other insulin regimens, such as the insulin 
pump, have replaced the long acting insulin for many patients (Phillip et al., 2007).  While there 
are many options for administering exogenous insulin, each patient’s requirements are different 
and their insulin regimens must be titrated accordingly.  The lack of consistent treatment options 
combined with the high risk for hypoglycemic attacks motivate the search for new treatments. 
T2DM begins with insulin resistance in the periphery, which leads to additional β cell 
stress leading to β cell death and/or dedifferentiation.  The first line of treatment consists of 
lifestyle changes such as diet and exercise.  This has shown to be very successful in patients who 
are able to adhere to such a regimen.  However, patients often are unable to maintain this course 
of treatment and medication becomes necessary.  While several classes of T2DM drugs exist, 
patients are usually started with a course of metformin.  Metformin has been shown to be a 
relatively safe drug and increases peripheral insulin sensitivity leading to a decreased demand on 
the pancreatic β cells.  Many patients are able to maintain euglycemia on metformin alone, but in 
cases where patients are not able to contain their disease through metformin and diet alone, 
several other drug classes are available [reviewed in (Inzucchi et al., 2012; Ismail-Beigi, 2012)].  
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Unfortunately, none of these drugs are considered perfect and many pose significant risks, 
including hypoglycemia.  In the case of thiazolidinediones, congestive heart failure and bone 
fractures are also risks.  Thus, significant research is being done on other forms of treatments. 
 
Islet Transplantation 
 While the current treatment of diabetes is focused on maintaining euglycemia, we have 
been unable to accurately restore the function of endogenous β cells.  Islet transplantation has 
been proposed as a better treatment strategy than the current regimens.   In this procedure, islets 
are isolated from donor pancreata and infused into the recipient’s portal vein.  The portal vein is 
the site of transplantation because it is easy to access and the liver is a highly vascularized organ, 
which is ideal for endocrine cells.  This protocol has been shown to be successful, and most of 
the patients are able to remain insulin independent for several years (Shapiro et al., 2000).   
While this procedure is extremely promising, the lack of available donor tissue, as well as a 
continued reliance on immunosuppressive therapies, has led to a search for additional sources of 
pancreatic islets.   
 Several potential methods of procuring more pancreatic β cells have been proposed, such 
as transdifferentiation of other organs, the expansion of the current β cell population, and 
differentiation of human embryonic stem (hES) or induced pluripotent stem (iPS) cells into β 
cells.  Many investigators have attempted to transdifferentiate liver cells into pancreatic β cells 
because both organs are derived from a common progenitor pool (Li, 2009; Nagaya et al., 2009; 
Tang et al., 2006).  Furthermore, the use of another organ from the same patient circumvents the 
need for immunosuppressive therapy.  Although these protocols have produced cells expressing 
and secreting insulin, the cells do not secrete insulin in a glucose-dependent manner, do not 
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express all of the genetic markers of mature β cells, and often express hormones found in other 
islet cells.  Although the liver seems to be an excellent candidate for creating a large pool of 
mature β cells, more work is needed to properly differentiate these cells.   
 Although other organs have been posited for the production of β cells, researchers have 
suggested that one might convert different pancreatic cell types into β cells.  Zhou and others 
attempted to transdifferentiate pancreatic acinar cells into β cells by virally infecting 2 month old 
mice with a mixture of transcription factors known to be important for pancreatic islet cell 
development, including Ngn3, MafA, and Pdx1 (Zhou et al., 2008).  They were able to convert 
approximately 20% of the infected exocrine cells into insulin producing cells.  Although the cells 
resembled mature β cells structurally, the cells were unable to maintain euglycemia in a 
streptozotocin-induced model.  Therefore, although this study shows promise towards 
transdifferentiation of the pancreatic exocrine tissue into endocrine tissue, additionaly 
experimentation is required to better understand the necessary factors required for this type 
transdifferentiation. 
 Others have suggested that existing β cells could be expanded in vivo.  Mouse studies 
have shown that insulin resistance as well as pregnancy are associated with increases in β cell 
replication (Sachdeva and Stoffers, 2009).  Non obese diabetic mice (NOD) have also shown an 
increase in β cell proliferation under increases in β cell inflammation (Sreenan et al., 1999).  
Moreover, mouse studies of TIDM, where the mice are treated with anti-CD3 antibodies to limit 
the β cell autoimmunity, have shown that the increase in β cell mass arises from replication and 
not differentiation (Sherry et al., 2006).  These studies have demonstrated that β cells have the 
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ability to proliferate but understanding the external cues that could be used to cause β cell 
replication have yet to be elucidated.   
 The greatest amount of work in the procurement of new β cells has gone into the 
differentiation of human embryonic stem cells into pancreatic β cells.  The current protocol 
attempts to mimic normal pancreatic development by adding various factors known to be 
important in differentiation (D'Amour et al., 2006). ES cells can be differentiated into pancreatic 
progenitors at a relatively high success rate; however, the differentiation of the pancreatic 
progenitors into mature and functional β cells has proven more elusive.  Currently, a small 
number non-glucose responsive insulin producing cells can be generated along with a large 
percentage of ghrelin and polyhormonal cells.  Further understanding of normal β cell 
development is necessary to further refine this protocol.   
 Although development of in vitro produced β cells from human ES cells remains 
promising, ethical and political issues have restricted the availability of these cells for research 
and potential therapeutics.  The differentiated cells would also not be derived from the patient’s 
own cells which could lead to rejection of the transplanted β cells.  These issues have been 
addressed by the development of induced pluripotent stem cells (iPS) (Takahashi and Yamanaka, 
2006).  In this protocol, isolated adult fibroblasts are dedifferentiated into a pluripotent state by 
the addition of four pluripoteny genes.  The iPS cell is then able to differentiate into all cell 
types.  Thus, the use of hES cells may not be needed and the patient will theoretically not require 
immunosuppression for β cell transplantation.  However, other concerns with iPS-derived islet 
transplantation exist.  iPS cells are pluripotent and have the ability to form cancers such as 
teratomas (Leon-Quinto et al., 2004).  Therefore, if the transplanted population contains even a 
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rare percentage of undifferentiated cells, the risk of teratoma development exists.  Moreover, the 
differentiated cells might not be full committed to the β cell lineage and thus could revert to an 
undifferentiated state leading to the formation of other tissue and potentially tumors.  The use of 
iPS cells is also problematic because the current protocols for differentiation employ the use of 
adenoviruses to infect the differentiating cells with the appropriate genetic factors necessary for 
differentiation although progress has been made with small molecules and RNA (Cho et al., 
2010; Okita et al., 2010; Warren et al., 2010).  As a result, the cells being created for 
transplantation contain factors such as the SV40 promoter, which has the potential to be 
tumorigenic.  Additionally, islet transplantation in T1DM patients presents a different limitation.  
These patients are diabetic as a result of autoimmune destruction of the β cell.  Transplantation 
could replace the lost β cells, but they would still be subject to the autoimmune destruction 
present in these patients.  Thus, more work is needed to understand the pathophysiology of 
autoimmunity in T1DM in order to prevent the destruction of transplanted islets.  However, the 
largest issue with using iPS cells as a treatment for diabetes is inefficient differentiation of iPS 
cells into β cells, once again underscoring the importance of studying how functional β cells 
form in the embryo. 
 
Pancreatic Endocrine Cell Differentiation 
 In the mouse, pancreatic development begins with formation of the pancreatic progenitor 
cell from the foregut endoderm at around embryonic day (E) 8.5. Pancreatic progenitor is marked 
by the transcription factors Pdx1, Ptf1a, Sox9, Nkx6.1, Nkx6.2, and Hnf1β (Haumaitre et al., 
2005; Henseleit et al., 2005; Kawaguchi et al., 2002; Seymour et al., 2007).  Knockout studies of 
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several of these factors including Pdx1 and Ptf1a have shown these transcription factors are 
indispensible for pancreatic formation.  The formation of the pancreatic progenitor cell marks the 
beginning of the primary transition of pancreatic development.  This stage is defined by 
extensive proliferation of the pancreatic progenitors.  This is then followed by the formation of a 
protruding column like epithelium, consisting of a trunk and tip domain, which will eventually 
differentiate into the exocrine and endocrine pancreas, respectively (Figures 1-1, 1-2).  The 
endocrine compartment begins with the expression of the transcription factor Ngn3.  These Ngn3 
expressing endocrine progenitor cells differentiation into the various endocrine cells of the 
pancreatic islet during the secondary transition from E12.5 through E16.5 
 
Islet Specific Transcription Factors 
 The differentiating islet is controlled by many transcription factors.  Some of these 
factors such as Ngn3, Isl1, and NeuroD affect the entire islet (Ahlgren et al., 1997; Gradwohl et 
al., 2000; Naya et al., 1997).  Others, such as Nkx2.2, Pax6, and Pax4 affect the vast majority of 
the endocrine cells in the islet (Collombat et al., 2003; Heller et al., 2005; Sussel et al., 1998).  
Additionally, some transcription factors such as Hlxb9 and Nkx6.1 affect a small percentage of 
the islet populations (Harrison et al., 1999; Sander et al., 2000).   For the purpose of this study I 
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At approximately E12.5, the pancreatic trunk-tip begins to differentiate and propagate in 
what is known as the secondary transition.  The transcription factor Ngn3 is expressed in the 
endocrine progenitor population, which forms from the trunk epithelium (Afelik et al., 2012; 
Gradwohl et al., 2000; Gu et al., 2002; Jensen et al., 2000; Schwitzgebel et al., 2000).  Mice 
lacking Ngn3 fail to form pancreatic endocrine cells and die postnatally due to hyperglycemia 
(Gradwohl et al., 2000).  Moreover, precocious Ngn3 expression results in an overabundance of 
endocrine cells.  In these experiments, overexpression of Ngn3 under the control of the Pdx1 
promoter led to an increase in predominantly glucagon producing α cells (Apelqvist et al., 1999; 
Schwitzgebel et al., 2000).  These studies demonstrate the key role for Ngn3 in endocrine cell 
differentiation.  However, some important questions remain.  First, since only α cells were seen 
in these overexpression studies, how do the other endocrine cells differentiate?  How does the 
timing of Ngn3 expression affect endocrine differentiation?  In order to answer this question, a 
study was performed to re-express Ngn3 in a Ngn3 null background during development 
(Johansson et al., 2007).  Ngn3 was fused to a tamoxifen-inducible estrogen receptor to allow for 
induction at discrete time points depending on the time of tamoxifen administration, and the 
fusion protein was directed by the Pdx1 promoter to allow for pancreatic specification.  When 
Ngn3 is induced at E8.5, the vast majority of endocrine cells are α cells, whereas when Ngn3 is 
initiated at E10.5, approximately 80% of the endocrine cells are α cells, and the remaining cells 
are β and PP cells in equal amounts.  Interestingly, as Ngn3 expression was induced at 
successively later stages of development, the proportions of endocrine cells continues to change, 
and the formation of non-α cells were formed at the expense of α cells (Johansson et al., 2007).  
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This study clearly demonstrates how the timing of Ngn3 expression is necessary for the 
appropriate formation of the correct proportions of different endocrine cells in the pancreatic 
islet and highlights the importance of transcription factor temporal regulation during 
development.   
Another interesting question that arose from these studies, as well as others, is whether 
Ngn3 cells are pluripotent or are they each already committed to a specific endocrine lineage? 
Desgraz and Herrera (Desgraz and Herrera, 2009) attempted to answer this question by using 
clonal analysis and binomial distribution statistics.  They used the mosaic analyses with double 
markers (MADM) technique to label a small percentage of Ngn3 cells and performed clonal 
analysis on this population.  These studies demonstrated that statistically, it is likely that each 
Ngn3 expressing cell is committed to a specific endocrine lineage (Desgraz and Herrera, 2009).  
Thus, although the Ngn3 expressing cell is considered to be the endocrine progenitor cell, each 
Ngn3 progenitor cell may already be committed to a specific endocrine lineage at or before the 
beginning of Ngn3 expression.  
 
Nkx2.2 
 Nkx2.2 is a member of the NK2 family of homeodomain transcription factors first 
identified in Drosophila (Kim and Nirenberg, 1989).  While originally implicated as a neuronal 
transcription factor (Price et al., 1992), it was later determined that Nkx2.2 is expressed in 
pancreatic cells in vitro (Rudnick et al., 1994).  This was confirmed by an in vivo mouse model 
showing that Nkx2.2 is not only expressed in the developing pancreas, but is also required for 
proper organ development (Sussel et al., 1998).  Sussel and others demonstrated that Nkx2.2 was 
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expressed in α, β, and PP cells starting at E9.5 but was excluded from δ cells.  Furthermore, 
mice lacking Nkx2.2 died in early postnatal life with severe hyperglycemia and hypoinsulinemia.  
Extensive analysis demonstrated that the Nkx2.2-/- lacked β cells, had a 90% reduction in α cell 
number, and a 50% reduction in PP cells.  However, the number of islet cells remained constant, 
and the majority of endocrine cells expressed the hormone ghrelin (Prado et al., 2004).  Ghrelin 
was known at the time to be expressed in the stomach and intestine where it played a role in 
hunger regulation (Kojima et al., 2001).  Subsequently, it was discovered that ghrelin was 
normally expressed in a small number of cells in the developing pancreas, leading to the 
classification of a new endocrine cell type – the ghrelin producing ε cells.  The Nkx2.2-/- mouse 
studies suggested that Nkx2.2 is required for the repression of the ε cell fate and for the activation 
of the α and β cell fates.   
 In order to better understand the mechanism behind the repression and activation states of 
Nkx2.2, Doyle and others generated an in vivo model of Nkx2.2 activation and repression.  They 
developed two transgenic lines by fusing the Nkx2.2 homeodomain to either the VP16 activator 
or the engrailed repressor domain under the control of the Pdx1 promoter for pancreas-specific 
expression.  The constitutive repressor complex partially rescued the null phenotype.  These 
mice had increased β and α cells and fewer ε cells relative to the null mice, but the β cells that 
did form lacked mature β cell markers such as MafA and Glut2.  The activator complex, on the 
other hand, had a similar phenotype to the null mice (Doyle et al., 2007).  These studies 
contributed to the hypothesis that Nkx2.2 acts a repressor early in β cell development and as an 
activator in β cell maturation.   
 




 Nkx2.2 is a 273 amino acid transcription factor with 3 regions of conserved homology: 
the tinman domain (TN), the homeodomain (HD), and the NK2 specific domain (SD) (Figure 1-
3A).  The homeodomain is responsible for DNA binding and is sufficient to bind to the Nkx2.2 
core-binding site, T(C/T)AAGT(G/A)(G/C)TT (Kim and Nirenberg, 1989).  The other two 
regions are thought to modulate Nkx2.2 function through their interactions with other proteins. 
The TN domain is analogous to the engrailed repressor domain of Drosophila and has been 
postulated to be responsible for gene repression through its interaction with corepressors such as 
Grg3.  In a recent study, it was determined that Nkx2.2 interacts with Dnmt3a, HDAC1, Nkx6.1, 
and Grg3, and that the TN domain was required for the direct interaction between Nkx2.2 and 
Grg3 (Papizan et al., 2011).  In the same study, analysis of mice lacking the TN domain 
(Nkx2.2TN/TN mice) revealed that their pancreatic islets displayed decreased β cells, increased e 
cells and, surprisingly, increased α cells.  Using lineage-tracing techniques it was discovered that 
the β cells were converting to α cells due to ectopic expression of Arx, a key α cell transcription 
factor.  The TN domain is required to interact with Grg3 for repression of genes, such Arx in the 
β cell population.  The differences between the Nkx2.2-/- and the Nkx2.2TN/TN mice provide 
interesting insights into the mechanism of Nkx2.2 action.  Because a dominant repressor 
derivative of Nkx2.2 partially rescues the loss of beta cells in the Nkx2.2-/- mice, Nkx2.2 was 
thought to act as a repressor for the formation of the β cell.  However, loss of Nkx2.2 TN-
mediated repressor activity did not result in a complete loss of β cells.  Therefore, either the TN 
domain is not the only Nkx2.2 repressor domain and/or repression is not the only pathway 
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necessary for β cell formation.  Studies involving the SD domain, as well as other portions of the 
Nkx2.2 protein, will be important to understand the nuances behind Nkx2.2 action.    
 The SD domain is also highly conserved amongst species and family members, but its 
function is relatively unknown and is the subject of this thesis (Figure 1-3B).   A few studies 
have been published concerning the SD domain, although they contain several limitations and do 
not fully reveal the function of the SD domain.  One particular study used an in vitro approach to 
test the ability of Nkx2.2 deletion constructs to regulate an artificial promoter containing tandem 
Nkx2.2 binding sites (Watada et al., 2000).  Removal of the SD domain led to an increase in 
promoter activation, whereas the SD domain alone was unable to repress luciferase activity.  
Furthermore, deletion of the acidic rich carboxy terminus (CT) led to a reduction in activation.  
Thus, it was suggested that the SD domain forms intramolecular interactions with the CT to 
reduce Nkx2.2 activation abilities.  Although this study posits some interesting roles for the SD 
domain, there are several limitations with the experiments, including the use of an artificial 
promoter element and the caveats normally associated with immortalized cell lines, which may 
lack necessary cofactors for correct SD domain function.  Thus, it is necessary to assess the 
regulation of bona fide Nkx2.2 targets and to perform in vivo functional studies to fully address 
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Additional studies investigated the SD domain in the Drosophila homolog to Nkx2.2, 
ventral nervous system defective (vnd) (Uhler et al., 2007) using ectopically expressed WT 
Nkx2.2 or Nkx2.2 with the SD domain deleted (ΔSD).  Flies containing vnd ΔSD had a decrease 
in downstream repression of intermediate neuroblasts defective (ind) and a decrease in activation 
of achaete.  This regulation was confirmed using in vitro luciferase assays demonstrate 
decreased repression of vnd downstream genes in the ΔSD flies.  Additional studies have 
demonstrated that an activating region is located towards the amino terminus of the protein and 
that removal of the SD domain reduces the activation potential.  This would suggest that the SD 
domain hinders the activation domain of Nkx2.2 through intramolecular interactions 
(Stepchenko and Nirenberg, 2004).  These studies demonstrate the intricacies of the SD domain 
and highlight the need for a more detailed in vivo study, which will be discussed in this thesis.  
 
Epigenetic Regulation 
 Epigenetics involves the cellular conditions that affect mitotic heritable gene expression 
without altering the DNA sequence (Holliday, 2006).  One of the first epigenetic marks to be 
discovered was DNA methylation (Holliday and Pugh, 1975) and was determined to play a 
critical role in gene expression through its role in cancer.  Feinberg and others first noted that 
tumor cells can lose DNA methylation marks while others have demonstrated that tumor 
suppressor genes can become hypermethylated leading to tumorigenesis (Feinberg and 
Vogelstein, 1983), [reviewed in (Feinberg, 2007)].   DNA methylation involves the covalent 
addition of a methyl group to the 5’ carbon site of cytosine, predominantly when the cytosine is 
followed by a guanine, termed a CpG.  Most CpGs in the mammalian genome are methylated.  
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However, there are regions of the genome that contain clusters of CpGs, and they were termed 
CpG islands (Gardiner-Garden and Frommer, 1987).  CpG islands are usually located in gene 
promoters or regulatory elements.  Furthermore, although most CpG islands are unmethylated, 
there are several cases where they are methylated, and this correlates with gene repression.  It is 
currently unclear whether methylation leads to gene repression or gene repression leads to 
methylation.  Another theory is that in order to maintain gene repression through cellular 
replication, the CpG island must be methylated to prevent gene de-repression.  Although the 
order of gene repression and methylation is up for debate, it is clear that DNA methylation is an 
important aspect of epigenetic regulation.   
 
DNA Methyltransferase 
 DNA methyltransferases (Dnmts) are enzymes that transfer the methyl group from S-
adenosylmethionine to the cytosine residue in CpGs. There are five Dnmt family members: 
Dnmt1, Dnmt2, and Dnmt3a, Dnmt3b, and Dnmt3L (Figure 1-4). Dnmt2 was recently identified 
as a member of a large family of proteins that are conserved from yeast to humans (Jeltsch et al., 
2006).  Goll and others further showed that Dnmt2 has methylation activity in mice on the tRNA 
of aspartic acid (Goll et al., 2006).  However, because Dnmt2 knockout mice have no obvious 
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In contrast to Dnmt2, the other Dnmt proteins have been extensively studied.  Dnmt 
proteins in mammalian cells consist of two major segments: an amino terminal region of variable 
length that contains several domains and a carboxy terminal region that is responsible for the 
catalytic activity of the methyltransferase.  The carboxy terminus is conserved from prokaryotes 
to eukaryotes and contains ten motifs that are required to be part of the Dnmt family.  The 
Dnmt3 family is considered to be one made up of de novo methyltransferases (Gowher and 
Jeltsch, 2001; Okano et al., 1998).  This family of proteins is responsible for the creation of 
methylation marks in the early stages of embryonic development and in the germ cells.  The 
Dnmt3 family consists of three genes: Dnmt3a, Dnmt3b, and Dnmt3L.  Unlike the other family 
members, Dnmt3L does not contain a catalytic domain and is thought to modulate the function of 
Dnmt3a and Dnmt3b.  Dnmt3a and Dnmt3b essential genes: Dnmt3a-/- mice die shortly after 
birth while Dnmt3b-/- mice are not viable past E9.5 (Okano et al., 1999).  Moreover, human 
mutations in DNMT3b lead to Immunodeficiency, Centromere instability, and Facial 
abnormalities (ICF) syndrome (Hansen et al., 1999; Okano et al., 1999; Xu et al., 1999).  These 
abnormalities result from the hypomethylation of the pericentromeric regions, which causes 
chromosomal rearrangements. In contrast to Dnmt3a and Dnmt3b, Dnmt3L-/- mice are viable 
(Hata et al., 2002).  However, male mice are sterile as Dnmt3L is required for spermatogenesis, 
and female mice fail to deliver live pups because the embryos die from neural tube defects 
(Bourc'his and Bestor, 2004; Bourc'his et al., 2001; Hata et al., 2002; Webster et al., 2005).  
These mouse and human studies demonstrate the biological significance of de novo methylation.   
While the Dnmt3 family is responsible for the initial methylation patterns, Dnmt1 is 
necessary to maintain and modulate methylation through its role as the maintenance 
methyltransferase.  Dnmt1 has been shown to preferentially bind hemimethylated DNA over 
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non-methylated DNA, and it is localized to the replication fork (Fatemi et al., 2001; Goyal et al., 
2006; Leonhardt et al., 1992).  Dnmt1-/- mice are embryonic lethal, dying by E10.5, suggesting 
that maintaining methylation patterns is necessary for viability (Li et al., 1992).  Moreover, 
embryonic stem cells lacking Dnmt1 are viable, but the cells die when a differentiation program 
is induced.   
While it is clear that Dnmt1 is responsible for the maintenance of methylation patterns, 
significant effort is underway to understand the modulation and specificity of Dnmt1 function.  It 
is currently believed that other proteins are needed for Dnmt1 regulation.  Dmap1, a 
transcriptional corepressor, is necessary for the binding of Dnmt1 near the replication fork during 
S phase (Rountree et al., 2000).  Dnmt1 also binds to Uhrf1, a protein that specifically binds to 
hemimethylated DNA, leading to proper recruitment of Dnmt1 (Bostick et al., 2007; Sharif et al., 
2007).  While there is good data showing that Dnmt1 is necessary for maintaining methylation 
patterns, little is known about its role in pancreatic development.  For example, how is Dnmt1 
recruited to specific promoters?  Do transcription factors recruit Dnmt1 or does Dnmt1 recruit 
the transcription factors?  Is methylation via Dnmt1 always associated with repression?   In this 
thesis I will demonstrate how Dnmt1 and Nkx2.2 interact in pancreatic development. 
 
DNA Methyltransferases in Islet Development 
 As discussed above, Dnmt proteins are important for normal development, and the early 
embryonic lethality associated with the null alleles preclude assessing their function in pancreatic 
development. To understand the role of DNA methylation in the pancreatic β cell, Dhawan et al. 
used the Cre-lox system to remove Dnmt1 specifically from the β cells (Ins:Cre; Dnmt1fl/fl) 
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(Dhawan et al., 2011).  Islets disrupted for Dnmt1 displayed aberrant expression of glucagon in 
the core of the islets as well as decreased insulin expression.  Moreover, the islets also contained 
cells co-positive for insulin and glucagon. Subsequent lineage tracing revealed that the co-
positive cells were derived from β cells, suggesting that Dnmt1 is required to maintain the 
identity of the β cell by promoting Insulin expression and inhibiting Glucagon expression.  
Interestingly, there was an upregulation of the α cell transcription factors Arx and MafB in the 
Dnmt1 mutant mice leading to the hypothesis that Dnmt1 is required to inhibit α cell gene 
expression in the β cell via DNA methylation.  Consistently, there was a reduction in the 
methylation of a CpG island in the promoter of Arx in the Dnmt1 deficient β cells and siRNA-
mediated reduction of Dnmt1 in a β cell line also caused a decrease in the methylation of the Arx 
promoter. Subsequently Papizan and others demonstrated that Dnmt3a is in a complex with 
Nkx2.2 on the Arx promoter (Papizan et al., 2011), suggesting that Dnmt3a may also be 
necessary for methylation of the Arx promoter and its repression in β cells.  Taken together, these 
studies demonstrate the importance of the Dnmt proteins and DNA methylation in the 
maintenance of proper islet cell identity.   
 
Methylation and Gene Regulation 
 Regulating gene transcription is of utmost importance during development.  Activating 
and repressing specific genes is necessary for the differentiation of cell types.  One major 
mechanism of gene regulation is DNA methylation (Suzuki and Bird, 2008).  Although most 
documented cases involve gene repression, it is possible that removal of DNA methylation 
would cause gene activation.  It is currently unclear how DNA methylation is regulated and what 
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mediates its cell and promoter specific regulatory activities.  What are the cofactors needed to 
direct DNA methylation towards specific genetic regions?  How are certain genes methylated in 
one cell type but not another?  In my thesis project I have begun to address some of these 
questions by studying the role of the Nkx2.2 SD domain and its interaction with Dnmt1.  
Characterizing the functional ramifications of this interaction, as well as determining how the SD 
domain is responsible for proper islet cell identity and fidelity will be extremely important for 
progressing the β cell field towards a full understanding of β cell development and the ability to 
differentiate β cell in vitro from iPS cells, a key goal towards the next major treatment of 
diabetes. 
Previous studies have suggested that the SD domain is involved in intramolecular control 
of Nkx2.2 activation.  Other studies have found that the SD domain can modulate intermolecular 
interactions.  Interestingly, my analysis has identified an important role for the SD domain in the 
specification and maintenance of the β cell fate, possibly through its interaction with Dnmt1 and 
the maintenance of appropriate DNA methylation.  I have found that mutation of the SD domain 
in mice causes a failure of proper β cell development leading to hyperglycemia at birth.  More 
interestingly, many of the remaining islet cells are polyhormonal, expressing multiple hormones 
and transcription factors not normally seen in a single pancreatic endocrine cell.  The 
polyhormonal cell type persists throughout the life of the mouse suggesting that this 
phenomenon is not a transient developmental phenomenon as seen in human development.  The 
polyhormonal phenotype can be attributed to the loss of interaction between Dnmt1 and Nkx2.2 
with mutation of the SD domain.  I hypothesized that this interaction is necessary for the proper 
methylation of islet specific genes.  I show that β cells from Nkx2.2SD/SD mice display decreased 
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methylation in non β cell genes, as well as an increase in non-β cell gene transcripts.  Thus, loss 
of Nkx2.2 regulated DNA methylation in the Nkx2.2SD/SD mice leads to the misexpression of 























Islet Cell Identity: The role of the Nkx2.2 NK2-SD Domain in Differentiating 
Endocrine Cells 
Joshua A Levine generated all data presented in this chapter except for the data included in 
Figure 1 (Jessica Shrunk created the mouse construct, Mark Magnusson’s lab made the mouse) 
Figure 6,7,10-11 (Assisted by Diana Garofalo), Figure 12 (Library Preparation assisted by Diana 
Garofalo, analysis performed by Tiziana Sanavia in the lab of Chris Stoeckert) 
 
Introduction 
 The mouse pancreas is composed of two distinct compartments: the exocrine pancreas 
which secretes digestive enzymes into the duodenum via the pancreatic ductal network and the 
endocrine pancreas, composed of the islets of Langerhans which are necessary for glucose 
homeostasis.  The embryonic pancreatic islet consists of 5 cell types: the insulin-producing β 
cell, the glucagon-producing α cell, the pancreatic polypeptide-producing PP cell, the 
somatostatin-producing δ cell, and the ghrelin-producing ε cell.  Defects in β cell development 
and function are associated with diabetes mellitus, a burgeoning disease affecting nearly 25 
million people in the United States.  Currently, the ideal treatment for diabetes would be 
replacement of the failing β cells.  However, a high quality source of replacement β cells has yet 
to be developed.  In an effort to generate new β cells, many studies have focused on 
understanding the complex genetic and epigenetic network involved in β cell development, a 
necessary step towards a successful β cell in vitro differentiation protocol.   
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Recent attempts to differentiate ES cells into glucose-responsive mature β cells have 
remained unsuccessful.  Current protocols attempt to recapitulate β cell development in vitro by 
treating cells with transcription factors and signaling molecules at successive stages of the 
differentiation process to sequentially induce pancreas stage-specific transcription factors 
(D'Amour et al., 2006).  Differentiation of ES cells towards pancreatic progenitors has been 
successful but differentiating these progenitors towards mature β cells has not yet been achieved. 
Current protocols result in a small number of non-glucose-responsive insulin-positive cells, α 
cells, and a large number of ε cells.  Furthermore, the vast majority of the cells produced in these 
protocols express multiple hormones, a phenomenon rarely seen in wild type organisms.  
Understanding pancreatic islet development will be crucial to overcome the failures of current in 
vitro β cell differentiation protocols. 
Nkx2.2 is an important transcription factor involved in pancreatic islet cell development. 
Nkx2.2 is expressed in the early pancreatic progenitor cell at embryonic day (E) 9.5.  Nkx2.2-/- 
mice fail to form β cells, resulting in hyperglycemia at birth and death shortly thereafter (Sussel 
et al., 1998).  These mice also have a 90% reduction in α cells, a 50% reduction in PP cells and a 
significant increase in ε cells (Prado et al., 2004).  Nkx2.2 is involved in the differentiation of 
many cell types in the CNS and pancreas through the activation or repression of cell type-
specific genes.  Prior studies in the pancreas have shown that Nkx2.2 acts as a repressor early in 
β cell development and potentially as an activator during β cell maturation (Doyle et al., 2007; 
Doyle and Sussel, 2007).  These functions may be mediated by distinct protein regions and/or 
cell-specific protein-protein interactions.  Nkx2.2 has 3 conserved regions: an amino-terminal TN 
domain, a homeodomain (HD), and a carboxy-terminal NK2 specific domain (SD).  The TN 
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domain has been shown to be important for transcriptional repression by Nkx2.2 through its 
recruitment of the Grg co-repressor proteins and a large repressor complex to silenced promoters 
(Muhr et al., 2001; Papizan et al., 2011).  Nkx2.2TN/TN mice have decreased β cells and increased 
α and ε cells at birth.  Furthermore, mutation of the TN domain also causes a β-to-α cell 
transdifferentiation (Papizan et al., 2011).  The HD domain is responsible for sequence specific 
DNA interactions and is sufficient for the binding of Nkx2.2 to DNA, in vitro (Watada et al., 
2000).  The function of the SD domain is not fully understood, however, it is over 95% 
conserved amongst species and Nkx2 family members (Uhler et al., 2007).  Prior in vitro studies 
have presented conflicting theories on the SD domain’s function. An in vitro study of mouse 
Nkx2.2 suggested that the SD domain is important for inhibiting Nkx2.2 activation through 
intramolecular interactions (Watada et al., 2000), whereas studies in Drosophila demonstrated 
that the SD domain was necessary for maintaining the interaction between the co-repressor 
protein groucho and the Nkx2.2 Drosophila homolog, vnd (Uhler et al., 2007).  However, caveats 
are associated with the experimental design of both studies and neither tested the functional 
activity of the SD domain in an endogenous setting.  Therefore, additional in vivo analysis of this 
domain in mice should help to clarify its function. 
During normal pancreatic development in the mouse, endocrine progenitor cells 
expressing Ngn3 differentiate into 5 distinct cell types.  Currently, there are many genetic models 
where endocrine cell ratios are altered; however, in each case the ability to specify and maintain 
distinct mono-hormonal cell populations is not affected.  For example, Nkx2.2-/- mice fail to form 
β cells but do form a small number of α cells, as well as a large number of PP cells and normal 
amount of δ cells.  They also contain a large number of ε cells.  However, all of these cell types 
are distinct and do not express multiple hormones (Prado et al., 2004). Similar to Nkx2.2-/- mice, 
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Pax6-/- mice fail to form appropriate numbers of β, α, and PP cells and compensate for the loss 
of certain endocrine cell types with an increase in the ε cell population (Heller et al., 2005; 
Sander et al., 1997).  Nkx6.1-/- mice, on the other hand, fail to form appropriate numbers of β 
cells during the secondary transition, while none of the other endocrine cells are affected (Sander 
et al., 2000).  Arx-/- mice at birth are missing α cells which are replaced by increased amounts of 
β and δ cells (Collombat et al., 2003).  Although much knowledge about the regulation of islet 
cell type specification has been gained from these mouse models, no explanation currently exists 
for the presence of polyhormonal cells in current in vitro β cell differentiation protocols.   
In this study we developed a mouse model containing a mutation of the SD domain at the 
endogenous Nkx2.2 locus.  These mice are hyperglycemic at birth resulting from a decrease in β 
cell formation beginning at E14.5.  Similar to current in vitro β cell differentiation protocols, 
these mice also contain polyhormonal cells (D'Amour et al., 2006).  Furthermore, we show that 
the SD domain is required for the interaction between Nkx2.2 and the maintenance DNA 
methyltransferase, Dnmt1.  The loss of this interaction leads to widespread DNA 
hypomethylation and ectopic expression of cell-type specific genes, such as the α cell gene Arx 
in the insulin producing cells of Nkx2.2SD/SD mice.  There also appears to be a downregulation of 
β cell genes.  These data demonstrate the importance of SD domain function in the appropriate 
specification and maintenance of islet cell-specific methylation patterns and endocrine cell 
identities during pancreas development.   
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Materials and Methods 
Generation of Nkx2.2SD mice 
 The Nkx2.2SD mice contain a mutation of the NK2-SD domain of Nkx2.2 in the 
endogenous locus.  The mice were created using the two-step recombination-mediated cassette 
exchange (RMCE) technology (Chen et al., 2011).  To create the Nkx2.2SD allele, overlap 
extension PCR was used to introduce a 99 bp synthetic peptide encoding the mutated SD domain 
and a unique SacII digestion site 
(GCCCGCACCGGCAGCCGCGGCAGCACCGGCAGCCGCAGCAGCAGGCGCCCCGGCA
CACGCGCTCAAAGCCCAGGACCTGGCAGCCGCCACCTTCCAGGCA) into the Nkx2.2 
locus.  Correct incorporation of the mutations in the Nkx2.2SD targeting vector were verified by 
DNA sequencing.  The Nkx2.2SD targeting vector was then electroporated into ES cells 
containing the Nkx2.2LCA allele (Arnes et al., 2012). A two-step positive-negative selection was 
used to identify embryonic stem (ES) cell clones that had undergone successful cassette 
exchange (Chen et al., 2011).  Positive clones were verified by PCR and southern blot analysis 
after digestion with SacII (data not shown).  Nkx2.2SD/+ ES cells were injected into C57Bl/6 
blastocysts and transferred to pseudopregnant C57Bl/6 mice.  Male chimeras were bred with 
female C57Bl/6 mice.  Agouti offspring were genotyped using PCR primers specific to the WT 
or Nkx2.2SD alleles (Figure 2-1B): oDB90 (WT 5’) GTGTGGCAGTGCCGGTCTG; oDB91 
(Nkx2.2SD 5’) GCGGCAGCACCGGCAGCCGCA; oDB 92 (WT and Nkx2.2SD 3’) 
GACAACGTTAACGTTGGGATG.  The FRT-flanked hygromycin cassette was removed by 
breeding to FlpE mice (Rodriguez et al., 2000).  All methodologies used in the production of the 
Nkx2.2SD mice were approved by the Vanderbilt University Animal Care and Use Committee. 
 




 All mice were maintained on a mixed strain background of Swiss Black (Taconic) and 
C57Bl/6 (Jackson).  Mice were housed and treated according to the Columbia University 
Institutional Animal Care and Use Committee approval protocol.  Genotyping of the Nkx2.2SD 
allele was performed using the primers ODB90-92.  Genotyping for the Nkx2.2+/-, Nkx2.2lacz/+, 
Ins:Cre, Ghr:Cre, and R26:Tom were described previously (Arnes et al., 2012; Herrera, 2000; 
Papizan et al., 2011).   
 
Immunohistochemistry 
 Frozen tissue: tissue was fixed in 4% paraformaldehyde (PFA) in phosphate buffered 
solution (PBS) for 4 hours or overnight at 4°C, washed in cold PBS, incubated in 30% sucrose 
overnight, and cryopreserved.  Paraffin embedded tissue: tissue was fixed in 10% neutral 
buffered formalin (Sigma) overnight at 4°C, rinsed in PBS, dehydrated with 30%, 50%, 70%, 
95%, and 100% ethanol, incubated in xylene, and embedded in paraplast.  7 µm sections were 
used for immunofluorescence.  Paraffin slides were rehydrated in xylene, 100%, 95%, 70%, and 
50% ethanol.  Slides were then treated with 10 mM sodium citrate (pH 6.0) in the microwave to 
perform antigen retrieval.  Frozen and paraffin slides were then washed in PBS, blocked in 5% 
serum in PBS + 0.3% Tween (PBST), and stained overnight at 4°C in the appropriate antibody.  
The primary antibodies used were: anti cleaved-caspase 3 (rabbit, 1:500, Cell Signaling), anti 
Chromogranin A (rabbit, 1:500, Millipore), anti Cpa1 (1:500, rabbit, R&D Systems) anti-
Glucagon (guinea pig, 1:1000, Millipore; rabbit, 1:1000, Pheonix), anti-Ghrelin (goat, 1:800, 
Santa Cruz Biotechnologies; rabbit, 1:200, Pheonix), anti-Insulin (guinea pig, 1:1000, Millipore; 
rabbit, 1:1000, Cell Signaling Technologies), anti MafA (rabbit, 1:500, Bethyl), anti Nkx6.1 
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(rabbit, 1:500 BCBC), anti-Pancreatic Polypeptide (rabbit, 1:200, Zymed), anti-Pdx1 (rabbit, 
1:1000, Millipore), anti-Phospho-histone-H3 (rabbit, 1:500, Millipore), anti-Somatostatin (rabbit, 
1:200, Pheonix; rat, 1:200 Abcam).  Sections were incubated with appropriate secondary 
antibodies for 2 hours at room temperature (Jackson Immunoresearch).  DAPI (1:5000, 
Invitrogen) was applied for 10 minutes after secondary antibody incubation.  Fluorescent images 
were obtained on a Leica DM5500 microscope and processed with LAF software.  Confocal 
images were acquired on Zeiss LSM710 and processed with Zen software.  For quantification, 
immunostained pancreata were counted manually on every fifth section (E12.5 and E14.5), or 
every tenth section (E18.5), throughout the entire pancreas (N=3).  The number of cells was 
normalized to total pancreas area (quantified in Adobe Photoshop).  All values are expressed as 
mean ± SEM.  Statistical analysis was performed using a two-tailed student’s unpaired t-test.  
Significance was achieved when P<0.05.   
 
RNA Analysis 
Total RNA was isolated from whole pancreatic tissue (RNeasy, Qiagen) and CDNA was 
prepared using the Superscript III kit (Invitrogen) and random hexamer primers.  Quantitative 
PCR was performed using 200 ng of cDNA, PCR master mix (Eurogenetec) and Taqman probes 
(ABI Assays on Demand).  See Table 2-1 for a list of primers used.  All genes were normalized 
to Cyclophilin B and were quantified using ABI prism software.  An n ≥ 3 was used for all ages.  
All values are expressed as mean ± SEM.  Statistical analysis was performed using a two-tailed 
student’s unpaired t-test.  Significance was achieved when P<0.05.  
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α-TC1 and Min6 cells were grown to ~ 75% confluence in a 15 cm culture dish and were 
formaldehyde-cross-linked according to the ChIP-IT Express kit (Active Motif).  Cross-linked 
chromatin was fragmented by sonication using a Diagnode BioRupter (20 min, 30 sec on/off).  2 
µg of mouse α-Dnmt1 (Abcam) was added to 20 µg of sheared DNA.  The antibody/chromatin 
complex was rotated overnight at 4°C.  Complexes were pulled down using protein G Dynabeads 
(Invitrogen).  Chromatin was washed, eluted, reverse-cross-linked, and treated with a protease.  
Chromatin was analyzed by quantitative real time PCR using SYBR Green fluorescence with the 
following primers: Arx (FWD): TCCTCCACCATTTGAGGGTA and (REV): 
GCAACTTGAGGGGGTACAGA.  All values are expressed as mean ± SEM.  Statistical 
analysis was performed using a two-tailed student’s unpaired t-test.  Significance was achieved 
when P<0.05.   
 
In Vitro Pulldown, Coimmunoprecipitation and Western Blot 
 In vitro translated protein was made using the TNT kit (Promega).  Protein was isolated 
from P0 mouse pancreata or Min6 cells transfected with myc tagged Nkx2.2 (WT or SD mutant) 
using the Nuclear Extract kit (Active Motif).  Protein complexes were added to 5 µg of mouse 
anti-Myc (Sigma), mouse anti-Dnmt1 (Abcam) or mouse anti-FLAG (Sigma, 1804).  
Protein/antibody complexes were pulled down using protein G DynaBeads (Invitrogen), washed, 
eluted, and run on a NuPAGE Novex 4-12 % Bis-Tris gel (Invitrogen).  Proteins were transferred 
onto a nitrocellulose membrane (GE Healthcare) and probed using mouse anti-Nkx2.2 
(Hybridoma), mouse anti-Myc (Sigma), mouse anti-FLAG (Sigma), mouse anti-Dnmt1 
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(Abcam), rabbit anti-LaminB1 (Santa Cruz Biotechnology), mouse anti-Dnmt3a (Abcam), or 
mouse anti-Dnmt3b (Imgenex). 
 
FACS 
 Pancreata were dissected from P0 Ins:Cre, R26 Tom or Ins:Cre, R26 Tom, Nkx2.2SD/SD 
mice and dissociated in Accumax (Invitrogen) supplemented with 25 µg of DNAse1 at 37°C for 
30 minutes.  Accumax treatment was stopped by addition of RPMI 1640 + 2% FBS 
supplemented with 25 µg of DNAse1.  Cells were resuspended in 350 µL of DPBS without ions 
supplemented with 1 µL of DAPI.  Sorted cells were collected in 500 µL of PBS for DNA or 750 
µL of Trizol (Qiagen) for RNA isolation.  For DNA isolation, cells were centrifuged, 
resuspended in lysis buffer supplemented with protease K and incubated at 55°C for 1 hour and 
phenol chloroform extracted.  DNA underwent bisulfite conversion using the Epitect Bisuflite 
conversion kit (Qiagen).  The Arx UR2 region of the promoter was amplified from the bisulfite 
converted DNA using the following primers: TCCTCCACCATTTGAGGGTA and 
GCAACTTGAGGGGGTACAG (Dhawan et al., 2011).  The PCR product was gel purified and 
cloned in to Topo 2.1 (Invitrogen).  At least 12 positive colonies were sequenced for bisulfite 
conversion.  Analysis was performed using QUMA (http://quma.cdb.riken.jp/).  For RNA 
isolation, cells were brought to 1 mL of liquid with addition of water.  200 uL of chloroform was 
added to the trizol mixture and the sample was vortexed.  Solution was separated using phase 
lock columns.  The aqueous layer was then purified using the RNeasy Micro Kit (Qiagen).  RNA 
was processed and analyzed using the protocol described above.   
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Methylation Sequencing Analysis 
 Whole pancreata were dissected from E15.5 mice and dissociated in lysis buffer 
supplemented with proteinase K for 1 hour at 55°C.  DNA was purified using phenol-
chloroform.  Sequencing libraries were prepared according to the reduced representation bisulfite 
sequencing preparation (Gu et al., 2011).  Sequencing was performed on a Genome Analyzer II 
(Illumina) using single reads and 36 cycles.  Analysis was done in collaboration with the 
University of Pennsylvania.   
Results 
Generation of Nkx2.2SD/SD mice 
 To understand the function of the Nkx2.2 NK-2 specific domain (SD), we generated mice 
containing alanine substitutions of the majority of the conserved amino acids within the SD 
domain, while leaving structural amino acids intact (Figure 2-1A-B).  We confirmed that 
neonatal Nkx2.2SD/SD mice expressed Nkx2.2 mRNA and protein at levels similar to their wild 
type littermates, suggesting that the mutation did not affect Nkx2.2SD protein expression or 
stability (Figure 2-1C-D).  Similar to the Nkx2.2-/- mice, the Nkx2.2SD/SD mice were born at 
normal Mendelian ratios and there was no apparent phenotype associated with the heterozygous 
Nkx2.2SD/+ mice at all ages tested (data not shown).  At birth, Nkx2.2SD/SD mice were significantly 
hyperglycemic and their fasting blood glucose levels continued to increase postnatally (Figure 2-
1E).  Unlike the Nkx2.2-/- mice, which die shortly after birth, the Nkx2.2SD/SD mice survived into 
adulthood, however these mice were infertile and died by approximately 6 months of age (data 
not shown).   
 
  36 
 
 
  37 
 
 
Nkx2.2SD/SD mice display a defect in β cell development 
 To determine the developmental defects that resulted in severe hyperglycemia at birth, 
we assessed pancreatic development in the Nkx2.2SD/SD mice during embryogenesis.  Although 
the Nkx2.2-/- mice display a developmental phenotype as early as E9.5 and insulin-expressing β 
cells are never formed (Sussel et al., 1998), the Nkx2.2SD/SD mice do not exhibit a loss in β cell 
numbers until E14.5 (Figure 2-2A-D,H). Beginning at E14.5, however, there is a 50% reduction 
in the number of insulin positive cells and 90% reduction in Insulin 2 mRNA transcript levels 
relative to wild type littermates.  These reductions were maintained at E18.5 (Figure 2-2E-H), 
suggesting that the SD domain is required for proper β cell formation as well as insulin 
expression. Unlike the Nkx2.2-/- mice that have a 90% reduction in α cells and a 50% reduction 
in PP cells, Nkx2.2SD/SD mice only have a reduction in b cell numbers and do not display any 
apparent α or PP cell phenotypes: α and PP cell numbers and Glucagon and Pancreatic 
Polypeptide mRNA transcript levels are equivalent to wild type levels (Figure 2-2A-F,I-J, 2-4A).   
The loss of endocrine cell populations in the Nkx2.2-/- mice is accompanied by a 
corresponding large increase in the ghrelin-expressing ε population, which persists until the mice 
die postnatally (Prado et al., 2004). However, the Nkx2.2SD/SD mice display only a small and 
transient increase in ε cells.  The elevation in ghrelin cell numbers persists through the secondary 
transition, but returns to normal levels by E18.5 (Figure 2-3). Consistent with a phenotype that is 
restricted to the β cell population, without a maintained increase in other endocrine cell types, 
the Nkx2.2SD/SD mice display a reduction in the total numbers of endocrine cells by the end of 
gestation, as evidenced by the significant decrease in expression of the pan-endocrine marker 
Chromogranin A (Figure 2-4,2-5).   
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The transient elevation in ghrelin-expressing cells was surprising given their perdurance 
in the Nkx2.2-/- mice. However, in wild type mice, ε cells are normally transient and give rise to 
PP and α cell populations (Arnes et al., 2012 in press).  To determine the fate of the expanded ε 
cell population present in the Nkx2.2SD/SD mice, we initiated genetic lineage analysis using 
Nkx2.2SD/SD; Ghrelin:Cre; R26:Tom mice to permanently mark the ε lineage (n=1).  This 
preliminary analysis suggested that similar to wild type mice, the ghrelin positive cells gave rise 
to subsets of the PP and α cell lineages (Figure 2-6C-F).  However, unlike the wild type 
situation, a rare number of ghrelin cells gave rise to δ cells (Figure 2-6A-B), but this event was 
not large enough to account for the disappearance of the increased ghrelin cell population.  We 
did not identify β cells derived from the ghrelin lineage, although since only one embryo was 
analyzed we cannot make any final conclusions (Figure 2-6G-H).  It was also possible that the 
increase and subsequent decrease of ghrelin cells was due to transient changes in ε cell 
proliferation followed by apoptosis.  However, at E16.5, ghrelin cells display only a slight 
increase in apoptosis and no change in proliferation rates (Figure 2-7).  Taken together, these 
data suggest that ghrelin is turned off in the developing pancreas of the Nkx2.2SD/SD mice, similar 
to late stages of normal pancreatic development. Further quantification analysis will be required 
to determine whether the ghrelin cells contribute to a greater ratio of PP and α cell lineages.   
 
Nkx2.2SD/SD mice fail to form distinct mono-hormonal islet cells 
 In the wild type mouse pancreas, five distinct mono-hormonal cell types with 
characteristic transcription factor profiles are formed from the Ngn3-expressing endocrine 
progenitor cells.  The exception is a small population of glucagon-ghrelin coexpressing cells that  
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is formed early, but resolved by birth when ghrelin expression is turned off (Heller et al., 2005). 
Notably, unlike other pancreatic mutant mouse models, the Nkx2.2SD/SD mice fail to form distinct 
monohormonal endocrine cell types.  Polyhormonal cells can be detected as early as e12.5, with 
30% of the insulin-producing cells expressing other hormones (Figures 2-8A-B’,I).  Furthermore, 
these polyhormonal cells are present throughout development, with 25% of all insulin-positive 
cells expressing the other pancreatic hormones at E18.5 (Figures 2-8C-D’,I); furthermore, all 
possible combinations of hormones could be detected in a single cell (data not shown).  In 
addition to hormone misexpression, many of the cell specific transcription factors were 
ectopically activated in incorrect cell types or polyhormonal cells.  For example, Pdx1, which 
normally marks β and δ cells at P0, was expressed in glucagon-producing cells (Figure 2-8E-’) 
and Nkx6.1, a β cell factor can be detected in glucagon-producing cells (Figure2-8G-H’).  There 
are several studies in human and mice to suggest that polyhormonal exist during the earliest 
stages of pancreatic development, and may represent precursor cells that resolve over time 
(Heller et al., 2005; Riedel et al., 2012).  To determine whether the polyhormonal cells observed 
in Nkx2.2SD/SD mice persisted postnatally, we assessed hormone expression in the islets of 2-3 
week-old Nkx2.2SD/SD mice.  All possible combinations of polyhormonal cells were seen 
postnatally, including triple positive and double positive cell populations (Figure 2-9A-D). 
Furthermore, these polyhormonal cells retained the misexpression of the islet transcription 
factors.  For example, MafA, which is exclusive to postnatal β cells, was expressed in a 
glucagon/somatostatin-coexpressing cell (Figure2-9E-F).  Therefore, the SD domain is required 
for the development and maintenance of distinct single hormone-expressing cells in the mouse 
pancreatic islet. 
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SD domain interacts with Dnmt1 
 Nkx2.2 is known to exist in a repressor complex that includes Grg3, HDAC1, and 
Dnmt3a and disruption of this complex in the Nkx2.2TN/TN mice leads to ectopic non-β cell gene 
expression in the β cell (Papizan et al., 2011).  These studies also demonstrated that the TN 
domain mediated a direct physical interaction with Grg proteins, but not HDAC1 or Dnmt3a. To 
begin to understand the molecular mechanisms underlying SD domain function, we investigated 
the interaction between the SD domain and the proteins present in the repressor complex with 
Nkx2.2.  We generated myc-tagged wild type and SD mutant proteins (mycNkx2.2 and 
mycNkx2.2SD) to perform in vitro pull down assays.  These studies confirmed that Nkx2.2 
interacted directly with Dnmt3a, Dnmt3b, HDAC1, and Grg3; however, mutation of the SD 
domain did not affect these interactions (Figure 2-10A and data not shown).  On the other hand, 
these studies demonstrated that the interaction between the maintenance methyltransferase, 
Dnmt1 and Nkx2.2 was dependent on the presence of the SD domain (Figure 2-10A,B).  The 
SD-dependent interaction between Nkx2.2 and Dnmt1 was also confirmed using co-
immunoprecipitation assays in transfected Min6 cells (Figure 2-10C).  Future studies will verify 
the SD-dependent interaction between endogenous Dnmt1 and Nkx2.2. 
 
Mutation of the SD domain leads to gene specific hypomethylation 
 The formation of polyhormonal endocrine cell populations in the Nkx2.2SD/SD mice 
coupled with the possibility that the Nkx2.2 SD mutation disrupts an interaction with Dnmt1, 
suggests that widespread loss of DNA methylation may be the cause of the dysregulated 
endocrine gene expression observed in the Nkx2.2SD/SD mice.  Consistent with this hypothesis, 
ablation of Dnmt1 in β cells caused hypomethylation of the α cell gene, Arx, and the subsequent 
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upregulation of the α cell genes Arx and MafB.  These α cell gene changes were accompanied by 
a downregulation of the β cell genes Pax4 and Pdx1 (Dhawan et al., 2011).  We first confirmed 
that Dnmt1 is recruited to the hypermethylated Arx promoter in β cell lines, but not to the 
hypomethylated promoter in α cell lines (Figure 2-11D).  To determine whether disruption of the 
SD domain, and presumably the interaction with Dnmt1 affected the methylation state of the Arx 
promoter in β cells, we performed bisulfite sequencing of the Arx promoter in β cells FAC sorted 
from Nkx2.2SD/SD Ins:Cre; R26:Tom mice.  Strikingly, demethylation of the Arx promoter was 
significantly increased in the Nkx2.2SD/SD versus the wild type beta cells (Figure 2-11A,B).  
Furthermore, the hypomethylation was associated with an upregulation of Arx mRNA expression 
in the β cell (Figure 2-11C).  Similar to the β cell specific knockout of Dnmt1, β cells in the 
Nkx2.2SD/SD mice also show a decrease in the β cell genes Insulin 2, Nkx6.1 and Pdx1.  Taken 
together these data suggest that the SD domain is required for establishing and/or maintaining the 
appropriate methylation patterns in the developing endocrine cell to repress non-β cell-specific 
genes.   
 
Nkx2.2SD/SD mice have global hypomethylation 
 Although we demonstrated that the mutation in the SD domain resulted in demethylation 
of the α cell specific gene Arx in the β cells, a general disruption of the interaction between 
Nkx2.2 and Dnmt1 would be expected to result in a global change in DNA methylation patterns.  
Furthermore, we hypothesized that the disruption of methylation patters would occur in the Ngn3 
endocrine population since we observed the presence of polyhormonal cells at their earliest stage 
of endocrine cell differentiation.  We performed reduced representation bisulfite sequencing on 
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whole pancreata at E15.5, a stage with the highest ratio of Ngn3 cells to total pancreas area to 
determine the global DNA methylation status of the Nkx2.2SD/SD mice.   Relative to wild type 
mice, Nkx2.2SD/SD mice had 4 times as many hypomethylated versus hypermethylated CpG’s 
(Figure 2-12).  Thus, disruption of the interaction between Nkx2.2 and Dnmt1 not only causes 
methylation changes at the Arx promoter, but also altered the methylation status of much of the 
genome.  This mass deregulation of the proper methylation marks in the developing endocrine 
cells likely contributes to cells ectopically expressing multiple hormones and non-canonical 
transcription factors.   
Discussion 
The Nkx2.2 SD domain defines the Nkx2 family and is thought to be functionally 
important due to its conservation amongst species and Nkx2 family members; however, its 
function remains elusive.  Prior studies have mainly focused on its molecular activity using in 
vitro models and regulation of artificial promoters (Stepchenko and Nirenberg, 2004; Uhler et 
al., 2007; Watada et al., 2000).  In this study we attempted to understand the role of the SD 
domain in the developing mouse pancreas by creating a mutation of the domain in the 
endogenous Nkx2.2 locus.  These studies demonstrated that the SD domain has two main 
functions in pancreas development: β cell formation and the correct specification of 
monohormonal endocrine cells.  
Nkx2.2SD/SD mice fail to form the proper number of β cells during development.  
Beginning at E14.5, and continuing throughout development, only 50% of the normal number of 
β cells are formed.  Furthermore, there is an even greater reduction in insulin expression with  
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10% of the normal Insulin 2 mRNA being present. Similar to the Nkx2.2-/- mice, the reduction in 
insulin-producing cells in the Nkx2.2SD/SD mice was associated with increased ghrelin cell 
numbers.  Surprisingly, however, ghrelin, which is persistently upregulated in the Nkx2.2-/- mice 
(Prado et al., 2004), was only transiently upregulated in the Nkx2.2SD/SD mice and ghrelin levels 
normalized by birth. The fate of these excess ghrelin cells has yet to be determined. In wild type 
mice, ghrelin-expressing ε cells normally differentiate into subsets of PP and α cells, but not into 
δ or β cells (Arnes et al., 2012, in press).  Shortly after birth, ghrelin expression is diminished 
and ε cells are rare in the adult islet.  Although early ε cell numbers are increased in the 
Nkx2.2SD/SD mice, wild type numbers of PP and α cells are derived from the ε cell lineage. It 
remains possible that increased numbers of ε cells in the Nkx2.2SD/SD mice contribute to modestly 
larger subsets of PP or α cells, but this contribution is not sufficient to cause statistically 
significant increases in these total endocrine cell populations.  Interestingly, unlike wild type 
mice, a small percentage of δ cells arise from the ε cells; however, this contribution is also too 
small to account for the fate of the excess ghrelin-expressing cells and may simply reflect the 
presence of ghrelin+/somatostatin+ polyhormonal cells during development.  We did not identify 
any β cells deriving from the ghrelin cell lineage. Similar to the ε-derived δ cells, it would be 
expected that some β cells would also result from the ghrelin+/insulin+ polyhormonal cell 
populations present in the Nkx2.2SD/SD mice during development.  We will have to analyze 
additional mice to make any final conclusions.  Furthermore, it may be difficult to definitively 
determine the fate of the excess ghrelin population since the lineage tracing studies are 
confounded by the presence of these polyhormonal cells, where ghrelin and other hormones are 
erroneously co-expressed in the same cells.   
  55 
 
 
These studies have also demonstrated that the SD domain is required for the creation of 
mono-hormonal endocrine cells.  During normal pancreatic development, Ngn3 endocrine 
progenitor cells differentiate into distinct islet cell types, each expressing a single hormone and a 
distinct set of transcription factors.  Furthermore, recent data have suggested that each Ngn3-
expressing cell is primed to form a single endocrine cell type (Desgraz and Herrera, 2009).  
Nkx2.2SD/SD mice contain polyhormonal cells as early as e12.5, when endocrine cells are 
beginning to differentiate, suggesting that the Ngn3-expressing endocrine progenitor cells are 
defective in the initial specification of single hormone expressing cells.  The identification of the 
SD-dependent interaction between Nkx2.2 and Dnmt1, the maintenance methyltransferase, also 
suggests that the formation of polyhormonal cells may be caused by a defect in DNA 
methylation.  Prior studies have suggested that cell-specific DNA methylation patterns are 
important for maintaining cellular identity.  For example, deletion of the methyltransferases 
Dnmt1 or Dnmt3a specifically in the β cells leads to an upregulation of α cell genes and the 
conversion of β cells into α cells (Dhawan et al., 2011; Papizan et al., 2011).  Surprisingly, 
neither of these genetic manipulations of demethyltransferases resulted in polyhormonal cells.  A 
possible explanation for the lack of polyhormonal cells in these models is that the 
methyltransferases were deleted from β cells after they had differentiated.  It is possible that once 
β cell differentiation has occurred, these cells are already restricted in their 
differentiation/transdifferentiation potential; reversion to immature β cells or transdifferentiation 
into α cells may be the only developmental option.  In contrast, disruption of the DNMT1 
interaction in the Nkx2.2SD/SD mice occurs much earlier in development and within the 
undifferentiated progenitor cell populations.  It is likely that because these endocrine precursors 
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possess wider differentiation potentials, they are inherently more plastic in their differentiation 
potential and retain the ability to misexpress β cell and non-β cell genes, which would lead to the 
formation of polyhormonal cells. This would predict that if one were to remove either Dnmt1 or 
Dnmt3a from the Ngn3 expressing endocrine progenitor population, polyhormonal cells would 
be generated.  However in the absence of this data, we can still conclude from the existing 
studies that maintenance of the correct DNA methylation patterns is necessary for the 
appropriate specification and maintenance of pancreatic islet cells.    
The interaction between the Nkx2.2 SD domain and Dnmt1 detailed in this study is 
consistent with prior experiments showing that the SD domain is important for groucho and 
intramolecular interactions (Stepchenko and Nirenberg, 2004; Uhler et al., 2007; Watada et al., 
2000).  Although our data suggests that the SD domain does not directly interact with Grg3, it is 
possible that the interaction between the SD domain and DNMT1 helps form or stabilize the 
interaction between the TN domain and Grg3 to form a large multi-protein repressor complex. 
We can test this model by investigating complex formation with the different Nkx2.2 mutant 
proteins in vitro and in vivo. Additional studies suggested there was an intramolecular interaction 
between the SD domain and an activator domain, which was postulated to mask the protein’s 
activation functions, it is possible that the SD-dependent interaction between Nkx2.2 and Dnmt1 
may compete with the binding of a putative co-activator protein to Nkx2.2 or may induce a 
conformational change in the protein structure to mask the activator domain.  Therefore, our data 
suggesting that the SD domain mediates the interaction between Nkx2.2 and Dnmt1 
complements prior functional and biochemical SD domain studies.  
Based upon our in vitro data, we expect that the interaction between Nkx2.2 and Dnmt1 
would be disrupted in the Nkx2.2SD/SD mice, which should ultimately have consequences on DNA 
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methylation states and gene expression.  The Arx promoter, a key α cell gene, was chosen as a 
candidate gene to test this hypothesis because it is regulated by cell-specific DNA methylation.  
The Arx promoter has been shown to be hypermethylated in β cells as opposed to α cells, which 
results in the repression of Arx in β and not in α cells (Papizan et al., 2011).  This differential 
methylation pattern was also associated with β cell-specific binding of the de novo 
methyltransferase, Dnmt3a, to the Arx promoter.  Furthermore, removal of Dnmt1 in the β cells 
in an in vivo mouse model resulted in hypomethylation of a CpG island in the Arx promoter 
specifically in the β cells (Dhawan et al., 2011).  In Nkx2.2SD/SD mice, we determined that the Arx 
promoter was hypomethylated and Arx was correspondingly upregulated in the β cells, 
suggesting that methylation changes have led to ectopic gene expression and polyhormonal cells.  
We further show that this methylation pattern is associated with the binding of Dnmt1 to the Arx 
promoter in β cell lines as opposed to α cell lines.  However, we have yet to determine whether 
mutations in the SD domain prevent the recruitment of DNMT1 to the Arx promoter or impairs it 
function.  Future studies will use ChIP assays on FAC sorted β cells to test whether the SD 
domain is necessary for the recruitment of Dnmt1 to the Arx promoter in vivo. In addition, since 
ectopic Arx can only account for the erroneous upregulation of alpha cell genes, additional genes 
must be dysregulated in the polyhormonal cells.  In an initial attempt to identify additional 
hypomethylated promoters, we assayed the mice for global methylation changes in whole 
pancreata at E15.5.  While these studies demonstrated that the Nkx2.2SD/SD mice contain 
relatively increased levels of hypomethylated CpGs compared to wild type animals, the use of a 
mixed population of cells precludes our ability to identify cell-specific DNA methylation 
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changes.  Future studies will focus on cell specific genome wide methylation pattern, which 
would be useful in understanding the role of the SD domain in a cell specific context. 
Although the interaction between Nkx2.2 and DNMT1 provides a plausible mechanism 
for the presence of polyhormonal cells in the Nkx2.2SD/SD mice, it is still unclear why these mice 
fail to form normal numbers of β cells.  It is possible that defective DNA methylation also 
contributes to this phenotype, which can be addressed by deleting DNMT1 from the Ngn3 
progenitor population.  Interestingly, unlike the Nkx2.2-/- mice, which do not form any β cells, 
the Nkx2.2SD/SD and Nkx2.2TN/TN mice form some β cells, albeit at lower levels. It is possible that 
the SD and TN domains are redundant in their functions to develop early β cell populations, and 
therefore simultaneous removal of both domains could recapitulate the complete β cell 
phenotype associated with the Nkx2.2-/- mice.  Alternatively, the function of the non-conserved 
regions of Nkx2.2 could be important in Nkx2.2 regulatory activities.  Future studies will address 
the loss of β cells in the Nkx2.2SD/SD mice. 
In conclusion, these data suggest that the SD domain plays a dual role in pancreatic 
development: β cell differentiation and the formation of mono-hormonal endocrine cells.  The 
mechanism for SD function in β cell differentiation remains to be elucidated.  Mutation of the 
SD domain in mice leads to the formation of polyhormonal cells through the destabilization of 
the interaction between Nkx2.2 and the maintenance methyltransferase Dnmt1.  This results in 
global hypomethylation as well as cell specific demethylation and upregulation of non-canonical 
genes such as Arx in the wrong cell type, in the case the β cell.  These studies have led to an 
important mechanism behind the inhibition of creating polyhormonal cells, a key factor that will 
be necessary to inhibit the formation of polyhormonal cells using in vitro differentiation 
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protocols, an elusive step in the creation of β cells for transplant into diabetic patients (D'Amour 


























Conclusions and Perspectives 
 
Diabetes mellitus, a multifactorial metabolic disorder, is a burgeoning disease affecting 
25 million people in the United States.  Diabetes can be associated with autoimmunity, insulin 
resistance, and defects in the pancreatic β cells.  My study predominantly addresses issues 
associated with β cell development and function.  One possible treatment for diabetes is 
replacement of the defective β cells; transplantation of donor islet cells has been achieved with 
relative success (Shapiro et al., 2000).  However, a paucity of available donor cells has led others 
to develop techniques to differentiate β cells in vitro from embryonic (ES) or induced pluripotent 
stem cells (iPS).  While these efforts attempt to mimic in vivo pancreatic development, they have 
been unsuccessful in differentiating mature, glucose-responsive, insulin- producing β cells.  The 
failure to form functional β cells highlights the need for a more complete understanding of islet 
cell development in order to further disease treatment.   
Nkx2.2 is a transcription factor that is indispensible for the developing islet.  Nkx2.2-/- 
mice completely lack β cells, have a vast reduction of α cells, a 50% reduction in PP cells, and 
display a corresponding increase in ε cells (Prado et al., 2004; Sussel et al., 1998).  Because 
Nkx2.2 affects multiple cell lineages and because its function within each cell are variable, it is 
possible that different regions of Nkx2.2 are responsible for the different spatial-temporal 
Nkx2.2 functions.  Understanding these different Nkx2.2 domains will be important for 
elucidating the intricacies of Nkx2.2 regulation.  In addition to the DNA binding homeodomain 
of Nkx2.2, two other conserved regions exist: the tinman domain (TN) and the NK2 specific 
domain (SD).  Analysis of Nkx2.2TN/TN mice demonstrated that the TN domain mediates the 
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formation of a repressor protein complex (Papizan et al., 2011).  Nkx2.2TN/TN mice also show a 
decrease in β cell formation and an increase in α and ε cell numbers.  Moreover, the Nkx2.2TN/TN 
mice display a β to α cell transdifferentiation resulting from the lack of repression of α cell 
genes in the β cells.  However, these mice do not phenocopy the Nkx2.2-/- mice suggesting that 
the TN domain is not the only domain of Nkx2.2 responsible for proper endocrine cell 
development and other regions of Nkx2.2 must be necessary for proper pancreatic formation.  In 
this study I showed that the highly conserved SD domain is required for β cell development and 
for the formation of monohormonal pancreatic endocrine cells, potentially through the regulation 
of cell and locus specific DNA methylation. 
 
Nkx2.2 SD domain Function 
To understand the role of the SD domain in vivo, I studied mice containing a mutation of 
the endogenous SD domain (Nkx2.2SD/SD).  Analysis of these mice revealed two striking 
phenotypes: the presence of polyhormonal cells that are not normally seen in the adult mouse 
islet and a great reduction in the overall numbers of insulin-producing β cells.   
While a fully differentiated islet normally consists of five different cell types that each 
express a unique hormone, the islets of the Nkx2.2SD/SD mice exhibit populations of cells that 
express combinations of several hormones and transcription factors normally only associated 
with a distinct hormonal subclass.  The occurrence of these polyhormonal cells indicates that key 
genetic networks necessary for cell-fate specification and differentiation are misregulated within 
the Nkx2.2SD/SD islet.  Furthermore, the identification of Dnmt1 as an Nkx2.2 SD domain binding 
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partner implicates this domain as a crucial modulator of pancreatic development through 
methylation patterning. 
 Methylation patterning is necessary for the consolidation of cellular identity.  Indeed, loss 
of the DNA methyltransferases Dnmt3a or Dnmt1 in the β cell results in the hypomethylation of 
the α-cell specific Arx promoter and consequent β to α cell transdifferentiation (Dhawan et al., 
2011; Papizan et al., 2011).  Furthermore, I have shown that mutation of the SD domain results 
in a decoupling of the interaction between Nkx2.2 and Dnmt1 leading to global and site-specific 
hypomethylation.  This disruption of proper methylation patterning, most probably within the 
Ngn3 expressing endocrine progenitor, leads to the formation of polyhormonal cells.  These 
studies highlight the importance of maintaining islet specific methylation patterning during 
endocrine development.  However, many questions regarding how epigenetics regulate islet 
differentiation remain.  Classically, distinct roles have been ascribed to the major DNA 
methyltransferase family members: the Dnmt3 family is required for de novo methylation, during 
early embryogenesis, while Dnmt1 is needed to maintain this methylation patterning during 
cellular replication.  Dnmt1 is ubiquitously expressed while Dnmt3a/b are expressed highly in 
progenitor cells and at lower levels in somatic cells (Jones and Liang, 2009).  It is thought that 
DNA methylation patterns are required to maintain gene repression after cellular replication.  
However, recent data have suggested DNA methylation is more complex.  While the classical 
definition of de novo methylation suggests that Dnmt3a would only be expressed during early 
embryogenesis, Dnmt3a has been shown to be present in pancreatic cell lines, as well as is P0 
pancreatic extracts (Papizan et al., 2011) suggesting additional functions beyond de novo 
methylation.  Moreover, removal of Dnmt3a and Dntm3b from ES cell lines result in progressive 
hypomethylation during successive cell passages, suggesting that the Dnmt3 family is needed for 
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maintenance of methylation patterning (Chen et al., 2003).  Other studies have suggested that 
Dnmt1 has de novo methylation properties.  Demethylation in Dnmt3a-/-, Dnmt3b-/- cell lines, 
treated with varying amounts of 5-AZA, a demethylase compound, showed remethylation of the 
genome after treatment suggesting that, in addition to maintenance methylation activity, Dnmt1 
has de novo methylation activity (Liang et al., 2002).  The varying functions of DNA 
methyltransferases add a level of complexity to the Dnmt1-Nkx2.2 interaction in the Nkx2.2SD/SD 
mice.  Does Dnmt1 act as a maintenance or de novo methyltransferase in different cell types 
during endocrine differentiation?  Is Nkx2.2 required to regulate Dnmt1 active type?  These 
questions will be addressed in future studies.   
In addition to DNA methylation patterning, gene repression is associated with other 
epigenetic changes such as histone modifications.  For example, trimethylation of lysine residue 
27 of Histone H3 (H3K27me3) has been associated with gene repression (Barski et al., 2007; 
Boyer et al., 2006; Lee et al., 2006; Roh et al., 2006).  Recent data in the lab has confirmed that 
H3K37me3 is bound to the hypermethylated Arx promoter in β cell lines as opposed to α cell 
lines (Papizan and Sussel, unpublished data) suggesting that histone modifications are also 
associated with repression of non-canonical genes in a cell specific context.  Moreover, studies 
have suggested that while histone modifications are associated with repression, DNA 
methylation is needed to maintain this repression through successive generations (Barski et al., 
2007; Jones and Liang, 2009).  These studies demonstrate the importance of the interplay 
between histone modification, gene regulation, and DNA methylation.  These data suggest there 
are potentially more complex methods of gene repression beyond the role of Dnmt1 in the 
formation of monohormonal pancreatic endocrine cells. Future studies will begin to address 
these mechanisms. 
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 In addition to the formation of polyhormonal cells, Nkx2.2SD/SD mice also display a 
reduction in the total number of β cells.  Candidate analysis of whole pancreata at multiple ages 
of gestation, as well as microarray analysis at E16.5, directly after the Ngn3 endocrine 
progenitors have differentiated, demonstrated that β cell associated genes were downregulated in 
the Nkx2.2SD/SD mice but that other pathways remained unchanged.  This phenotype is not 
observed in the Nkx2.2-/- animals, which do not form β cells throughout development.  While the 
persistence of a small β cell population in the Nkx2.2SD/SD mice implies that other Nkx2.2 protein 
domains may also help establish the β cell fate, the function of the other Nkx2.2 domains in the 
initiation of β cell differentiation is still under investigation.  To address this issue, transcriptome 
analysis could be performed on sorted Ngn3 endocrine progenitor cells from the Nkx2.2SD/SD 
mice to understand the genetic changes that lead to a reduction in β cell formation.  However, 
using isolated cell populations from the Nkx2.2SD/SD mice has its own limitations because these 
cellular populations are being studied in the context of a ubiquitous SD domain mutation.  To 
begin to understand the role of the SD domain within specific cell types, the Cre-LoxP system 
can be used to mutate the SD domain within a specific cell population.  In this experiment, the 
Nkx2.2flox allele would be used in conjunction with the Nkx2.2SD allele.  Because the Nkx2.2SD/- 
mice are phenotypically indistinguishable form the Nkx2.2SD/SD mice, and because the Nkx2.2SD/+ 
mice have no apparent phenotype, we can use an Nkx2.2SD/flox mouse to mutate the SD domain 
within a specific domain.  To determine the role of the SD domain within the Ngn3 endocrine 
progenitor pool, where I hypothesize that the polyhormonal cell fate is specified, a Ngn3:Cre 
allele would be used.  Mutating the SD domain only in β cells using the Ins:Cre allele could also 
elucidate the role of the SD domain in the consolidation and maintenance of β cell identity.  
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However, this experiment would only detail the role of the SD domain in β cell function and not 
in β cell formation.  Alternatively the Pdx1:CreER allele could be used to induce SD domain 
mutation at the onset of β cell differentiation, in the pre-β cell.  Appropriate timing of the 
tamoxifen treatment will be challenging, as early induction could lead to widespread pancreatic 
SD mutation and late induction could result in SD mutation in the already differentiation β cells.  
Despite these caveats, this experiment could provide important insight into the spatial and 
temporal requirements SD function in the development of the β cell. 
One potential limitation associated with our studies is the use of a ubiquitous mutation; 
SD function is disrupted in all Nkx2.2-expressing tissues, including the nervous and intestinal 
systems.  It is unclear whether the function of Nkx2.2 in these other systems influences Nkx2.2 
function in the pancreas.  Although the tissue specific experiments described above, partially 
alleviate this issue, the Cre inducers are not pancreas specific.  For example, the Ngn3:Cre allele 
is also expressed in the nervous and intestinal systems.  If warranted, future studies employing a 
pancreas specific SD mutational analysis may be informative. 
In Vitro Differentiation of β  Cells 
Understanding the details of pancreatic development has allowed investigators attempting 
to differentiate β cells in vitro by mimicking in vivo development.  Current protocols have 
focused on the differentiation of embryonic (ES) or induced pluripotent (IPS) stem cells into 
mature, glucose responsive β cells (D'Amour et al., 2006).  These protocols focus on a wide 
variety of extracellular signaling molecules to differentiate the stem cells towards a β cell fate, 
including Activin, Wnt, Fgf, Retinoic Acid, and others.  However, these differentiation protocols 
fail to produce functional β cells and the majority of the cells found at the end of the 
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differentiation protocol are polyhormonal.  Analysis of Nkx2.2SD/SD mice has demonstrated that 
non β cell genes are repressed in a methylation specific manner during the differentiation of the 
β cell.  Lack of this directed methylation patterning results in the formation of polyhormonal 
cells.  Because both of these systems produce polyhormonal cells, it is possible that non-β cell 
genes are not being methylated and subsequently repressed during the in vitro differentiation 
protocol.    
Investigators have been aware of the possibility of methylation patterning being 
important for the in vitro differentiation protocol.  However, most studies have focused on global 
methylation changes using molecules such as HDAC inhibitors (Christensen et al., 2011).  
However, my studies have demonstrated the need to locally alter methylation patterning.  
Because methylation is often associated with gene repression, site directed gene repression might 
lead to similar results as local methylation changes.  Currently, it is unclear how to alter 
methylation patterning in a directed fashion, but future technologies will allow us to attempt 
these experiments.  It is also possible that modulating the extracellular signaling pathways that 
influence DNA methylation and/or gene repression could help in the differentiation protocol.  In 
addition, we currently do not know the signaling pathways that are affected in the Nkx2.2SD/SD 
mice that lead to a failure to develop appropriate numbers of β cells, as well as the formation of 
mono-hormonal cells.  The potential signaling pathways altered in the Nkx2.2SD/SD mice may be 
altered in the Ngn3 endocrine progenitor population, and understanding the genetic changes 
specifically within this population will elucidate pathways that could be more easily modulated 
in the in vitro differentiation process.  Therefore, the mechanisms associated with the phenotypic 
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Diabetes remains an escalating disease in the United States.  Its association with β cell 
failure has led investigators to attempt to differentiate β cells in vitro for transplantation into 
diabetic patients.  However, current differentiation protocols have failed to create glucose 
responsive, mature, β cells.  Understanding the intricacies of in vivo pancreatic development is of 
utmost importance for the improvement of these differentiation protocols. In the study of the SD 
domain of Nkx2.2, I have uncovered the role of methylation in the developing islet.  While many 
investigators have focused on gene activation and which genes are necessary for proper β cell 
differentiation, the appropriate repression of genes during development has often been 
overlooked.  The failure of the Nkx2.2SD/SD mice to form single hormone expressing pancreatic 
endocrine cells have highlighted the importance of proper methylation patterning in the 
repression of genes that need to be inactivated to promote appropriate cell specification.  
Therefore, these studies have highlighted the role of gene methylation and repression in the 
developing islet.  These data will enable refinement of the in vitro β cell differentiation protocol, 
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Transcriptome Analysis of Nkx2.2SD/SD Mice 
Joshua Levine generated all data except for the microarray analysis, which was performed by 
the University of Pennsylvania School of Medicine’s IDOM-DRC Functional Genomics 
Core.  
 
 Phenotypic analysis of Nkx2.2SD/SD mice discussed in chapter 2 detailed a candidate gene 
analysis that demonstrated there was a reduction in the expression of β cell genes, such as Insulin 
2 and Nkx6.1.  The gene expression changes were associated with a 50% reduction in insulin-
expressing cell numbers and a 90% reduction in Ins2 mRNA levels.  To begin to fully 
understand the phenotypic profile of the Nkx2.2SD/SD mice, we performed whole genome 
expression analysis. We chose to analyze whole pancreata at E16.5, a stage where many of the 
Ngn3 expressing endocrine progenitor cells have begun to differentiate, but exocrine 
differentiation has yet to occur.  Pancreatic tissue was dissected Nkx2.2+/+ and Nkx2.2SD/SD mice 
(N=3).  RNA was prepared and hybridized to an Agilent Whole Mouse Genome Microarray 
4x44K [G4122F].  The analysis was performed by the University of Pennsylvania School of 
Medicine’s IDOM-DRC Functional Genomics Core.  The microarray dataset can be found at: 
http://www.betacell.org/resources/data/studies/view/study_id/4258.   
 
β-cell Specific Genes 
 Consistent with candidate mRNA analysis (chapter 2), the microarray revealed several β 
cell genes were downregulated in the Nkx2.2SD/SD mice.  Insulin 2 was decreased in 11 probes 
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confirming the β cell defect.  Insulin 1 and NeuroD1, other β cell genes were also found to be 
downregulated in the Nkx2.2SD/SD mice.  Surprisingly, Nkx6.1 and Pdx1, two additional β cell 
genes were not significantly altered in Nkx2.2SD/SD mice.   Ghrelin, Glucagon, and Pancreatic 
Polypeptide levels did not differ from wild type mice.  Somatostatin was increased in the 
Nkx2.2SD/SD mice but we were unable to confirm this result with qRT-PCR analysis (Figure A-
1).  Taken together, these data add supporting evidence for the role of the SD domain in β cell 
development, but not the other endocrine cell types.   
 
Non-Annotated Genes 
 The largest proportion of gene changes in the Nkx2.2SD/SD mice were unannotated 
including many non-coding RNAs, suggesting that the SD domain is responsible for the 
regulation of non-coding RNAs.  Several forms of non-coding RNA exist including shRNA and 
miRNA.  These various RNA’s are thought to play a role in genetic regulation either by binding 
to the mRNA itself or to the various locations on the DNA genome, in a similar fashion to 
transcription factors.  Others have postulated that these RNAs can bind to other proteins 
affecting their function.  While it is unclear what specific non-coding RNAs are affected by the 




The highest and third highest downregulated RNA found in the array was a pseudogene 
located upstream of the coding region for Gon-4-Like (Gon4L). In the hematopoietic system, 
Gon4L has recently been shown to be associated with HDAC1, a known Nkx2.2 cofactor ((Lu et 
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al., 2011; Papizan et al., 2011).  HDAC1 is known to be involved in epigenetic regulation, the 
same pathway that was shown to be implicated in the Nkx2.2SD/SD mice through the SD 
dependent interaction of Nkx2.2 and Dnmt1.  Taken together, these data suggest another potential 
mechanism for the epigenetic regulation of pancreatic endocrine cell development by the SD 
domain.   
 
Conclusions and Future Directions 
 The microarray results have confirmed our prior candidate analysis showing a decrease in 
several β cell genes in the Nkx2.2SD/SD mice.  Two β cells genes, Nkx6.1 and Pdx1 remain 
unchanged suggesting that only a portion of β cell differentiation is affected.  However, these 
data do not fully address the polyhormonal phenotype.  For example, one would expect non β 
cell genes to be upregulated since the insulin+ cells express other hormones and transcription 
factors not normally seen in the β cell.  However, these same genes may be downregulated in 
their own cell type, which is also becoming polyhormonal.  In order to address this issue, whole 
genome transcription analysis would have to be performed on individual cell populations.  For 
example, understanding the transcriptional differences within the Ngn3 expressing progenitor 
cell population could elucidate some of the pathways that have been altered which results in the 
production of polyhormonal cells.  As a result, although the microarray has confirmed our earlier 
β cell phenotype, analysis of individual cell populations is needed to fully understand the 
complex phenotype associated with the Nkx2.2SD/SD mice. 
 
 




Figure A-1: Somatostatin is unchanged in Nkx2.2SD/SD mice at E16.5.  qRT-PCR of mRNA 
extracted from whole pancreata at E16.5 showing equivalent amounts of Somatostatin transcript 



































Proteomic Analysis of Nkx2.2 SD Domain Binding Partners 
 The Nkx2.2 NK2-SD (SD) domain is highly conserved amongst species and Nkx2 family 
members (Figure 2-1A).  Prior studies have suggested that the SD domain regulates cofactor 
binding.  However, these cofactors have yet to be elucidated.  Understanding the Nkx2.2 binding 
partners that are regulated by the SD domain will lead to a better understanding of the function 
of the SD domain.   
 To investigate the SD domain interacting factors, in vitro pulldown assays followed by 
mass spectrometry were utilized.  mycNkx2.2, mycNkx2.2SD, or Myc was in vitro translated 
(Promega TNT).  The protein was mixed with nuclear extract from 16 150 mm confluent plates 
of Min6 cells.  The mixture was immunoprecipitated using 25 ug of mouse-α-myc antibody 
(Sigma) and exposed to SDS-PAGE analysis followed by coomassie staining.  SDS-PAGE 
samples were digested and analyzed by mass spectrometry at the Columbia University Medical 
Center Protein Core Facility (Table B-1).   
 
Histone Variants 
 One of the more interesting cluster of proteins identified in this study was the Histone H1 
variant group.  Mutation of the SD domain caused a loss of interaction between Nkx2.2 and 
either Histone H1.1 or Histone H1.2 and a gain of interaction with Histone H1.4.  Histone H1 
proteins have been known to play a role in chromatin packaging but more recently different 
variants have been shown to affect differential gene regulation (Brown, 2003; Bustin et al., 2005; 
Terme et al., 2011).   Histone H1.1 was recently shown to be differentially expressed in 
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pluripotent cells as opposed to somatic cells suggesting that it is important for maintenance of 
pluripotency (Terme et al., 2011).  On the other hand, histone H1.2 and H1.4 were found to be 
expressed in both somatic and pluripotent cells suggesting that they are necessary for cellular 
maintenance.  Expression levels of these various histone variants also changes amongst cell types 
and thus, they are needed at various points in cellular development (Kratzmeier et al., 1999; 
Meergans et al., 1997).  The polyhormonal cells seen in the Nkx2.2SD/SD mice could partially 
result from the misregulation of appropriate Histone H1 variants.  Therefore, the ability of the 
Ngn3 endocrine progenitor cell to differentiate into single hormonal expressing cells requires the 
expression of specific Histone H1 variants and the SD domain is necessary for this process.   
 
Other SD Interacting Proteins 
 Mutation of the SD domain of Nkx2.2 led to some other potential interacting factors.  
These include proteins involved in RNA processing and binding such as Elavl1, Eif2s1, Hnrnpu, 
Dhx9, and Ddx21.  Furthermore, Hmgb2, a protein involved in controlling cell growth and 
proliferation was also bound to Nkx2.2 in an SD dependent manner (Franklin et al., 2012). 
Nop58, a factor involved in snoRNA binding was also found to be a potential SD interacting 
factor.  These potential binding factors could account for the phenotype associated with the 
Nkx2.2SD/SD mice. 
 
Gain of Function Proteins 
 Mutation of the SD domain also caused a gain of protein binding suggesting that the SD 
domain is also necessary to inhibit Nkx2.2 cofactor interactions.  For example, Mlxipl, a factor 
involved in regulation β cell proliferation potentially binds Nkx2.2SD, suggesting a potential 
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mechansism for the dysregulation of β cell development in Nkx2.2SD/SD mice (Metukuri et al., 
2012).  Moreover, Top2b, a protein involved DNA replication, also bound to Nkx2.2SD further 
implicating the SD domain in the dysregulation of β cell proliferation during development.  
Thus, mutation of the SD domain could recruit additional cofactors to Nkx2.2 that would cause 
an imbalance of necessary proliferation factors in the development of the β cell.   
 
Conclusions and Future Directions 
 This study demonstrates some of the potential binding factors of Nkx2.2 that are 
dependent on the SD domain.  While the candidate approach detailed in Chapter 2 demonstrated 
that the SD domain is responsible for the interaction between Nkx2.2 and Dnmt1, all aspects of 
the Nkx2.2SD/SD phenotype are not fully explained.  As a result, we performed this non-candidate 
cofactor binding experiment.  However, several caveats still exist with this experiment.  First, 
Nkx2.2 was found in the pull down only in the wild type situation and not in the Nkx2.2SD pull 
down.  As a result, it is possible that some of the potential SD dependent Nkx2.2 cofactors are 
false positives.  Furthermore, the largest percentage of the proteins that resulted from these 
experiments were IgG associated proteins which inhibits the ability of the mass spectrometer to 
discern less concentrated proteins.  In future experiments, IgG bands on the SDS-PAGE gel can 
be physically removed, but this would also eliminate any potential Nkx2.2 cofactor of the same 
molecular weights.  Another caveat of these studies is that the experiment was only performed 
once.  Thus, any potential SD dependent interactions would have to be confirmed either in a 
candidate approach or by repeating the mass spectrometry experiment.  Although limitations 
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Lost with SD mutation 
Sequence Name 
ELAV-like protein 1 OS=Mus musculus GN=Elavl1 PE=1 SV=2 
Eukaryotic translation initiation factor 2 subunit 1 OS=Mus musculus GN=Eif2s1 
PE=1 SV=3 
Heterogeneous nuclear ribonucleoprotein U OS=Mus musculus GN=Hnrnpu PE=1 
SV=1 
High mobility group protein B2 OS=Mus musculus GN=Hmgb2 PE=1 SV=3 
Histone H1.1 OS=Mus musculus GN=Hist1h1a PE=2 SV=2 
Histone H1.2 OS=Mus musculus GN=Hist1h1c PE=1 SV=2 
Isoform 2 of ATP-dependent RNA helicase A OS=Mus musculus GN=Dhx9 
Nucleolar protein 58 OS=Mus musculus GN=Nop58 PE=1 SV=1 
Nucleolar RNA helicase 2 OS=Mus musculus GN=Ddx21 PE=1 SV=3 
 Gained with SD mutation 
Sequence Name 
DNA topoisomerase 2-beta OS=Mus musculus GN=Top2b PE=1 SV=2 
Histone H1.4 OS=Mus musculus GN=Hist1h1e PE=1 SV=2 
Isoform 2 of Carbohydrate-responsive element-binding protein OS=Mus musculus 
GN=Mlxipl 
Isoform 2 of Zinc finger protein castor homolog 1 OS=Mus musculus GN=Casz1 
 
Table B-1: List of proteins identified by mass spectrometry.   
 
 
 
 
 
